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Abstract
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Introduction—TRPM2 channels have been suggested to play a role in ischemic neuronal injury,
specifically in males. A major hindrance to TRPM2 research has been the lack of specific TRPM2
inhibitors. The current study characterized the specificity and neuroprotective efficacy of a novel
TRPM2 inhibitor.
Methods—Fluorescent calcium imaging (Fluo5F) was used to determine inhibitor efficacy of the
TRPM2 peptide inhibitor (tat-M2NX) in HEK293 cells stably expressing hTRPM2. Adult (2–
3months) and aged (18–20 months) mice were subjected to 60 min middle cerebral artery
occlusion (MCAO) and injected with tat-M2NX, control scrambled peptide (tat-SCR) or
clotrimazole (CTZ) either 20 min prior or 3 h after reperfusion. Infarct size was assessed using
TTC staining.
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Results—TRPM2 inhibition by tat-M2NX was observed by decreased Ca2+ influx following
H2O2 exposure human TRPM2 expressing cells. Male mice pre-treated with tat-M2NX had
smaller infarct volume compared to tat-SCR. No effect of tat-M2NX on infarct size was observed
in female mice. Importantly, male TRPM2−/− mice were not further protected by tat-M2NX,
demonstrating selectivity of tat-M2NX. Administration of tat-M2NX 3 h after reperfusion
provided significant protection to males when analyzed at 24 h or 4 days after MCAO. Finally, we
observed that tat-M2NX reduced ischemic injury in aged male mice.
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Conclusions—These data demonstrate the development of a new peptide inhibitor of TRPM2
channels that provides protection from ischemic stroke in young adult and aged male animals with
a clinically relevant therapeutic window.
Keywords
TRPM2 channel; Experimental stroke; Cerebral ischemia; Aging; Sex

1. Introduction
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Stroke is the second leading cause of death worldwide with a significant financial burden
and poor life quality among recovered patients due to cognitive disability (Mozaffarian et al.,
2015). Unfortunately, the clinical pharmacological tools available to reduce brain injury and
treat patients with stroke are extremely limited, possibly due to the vast majority of
experimental stroke studies using young adult male animals (Herson and Traystman, 2014).
In contrast, two of the most important and non-modifiable risk factors for stroke are age and
gender (Romero et al., 2008). Clinical stroke is well known to affect the elderly
(Mozaffarian et al., 2015), with the risk for stroke doubling every decade after age 55 years
old (Wolf et al., 1992), independent of other risk factors (Romero et al., 2008). Aging has
numerous effects on the brain, including numerous biochemical changes, neurochemical
changes, alterations in blood flow and decreases in white matter, to name a few. Further,
stroke is well known to affect men to a larger extent than women until later in life where the
rate of stroke increases in elderly women (Reeves et al., 2008). This observation is likely due
to effects of androgens and estrogen in cell death pathways (Herson et al., 2009). However,
most neuroprotection investigations either have not used female animals or have not been
powered to find differences between sexes in human trials. Thus, it is critical to more
accurately model the human patient population in order to determine the therapeutic
potential of any new compounds.
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Transient receptor potentialM2(TRPM2) channels are non-selective cation channels
activated by ADP ribose (ADPr) (Perraud et al., 2001). ADPr is generated by PARP-1 in
response to oxidative stress and cerebral ischemia, which is particularly relevant in the
setting of reperfusion injury after ischemia (Shimizu et al., 2013). Inhibition of TRPM2 ion
channels with clotrimazole (CTZ) or genetic knockdown reduces ischemic injury in males,
but not females (Jia et al., 2011; Verma et al., 2012; Shimizu et al., 2013; Quillinan et al.,
2014; Shimizu et al., 2016). While we have previously shown that CTZ can be administered
up to 2 h after onset of ischemia in stroke models (Shimizu et al., 2013), we have not
previously investigated whether inhibiting TRPM2 at more extended time points provides
neuroprotection. Even though TRPM2 appears to be a viable target for therapeutic
interventions for stroke in males, preclinical studies have been limited by the lack of a
specific inhibitor. Therefore, one goal of this study was to develop and test a membranepermeable, selective inhibitor of TRPM2 ion channels that can be used to further the
understanding of TRPM2 in neuronal injury following focal cerebral ischemia. Targeting the
Nudix motif located on the C-terminal of the TRPM2 channel that directly binds ADPr, we
designed a peptide that would inhibit TRPM2 activity and attached it to a tat domain of HIV
to promote cell permeability (tat-M2NX). The current study uses both sexes and aged mice
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to show that tat-M2NX is a novel neuroprotective agent with a clinically relevant therapeutic
window.

2. Methods
2.1. Animals

Author Manuscript

All experimental protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Colorado and adhered to the National Institute of
Health guidelines for the care and use of animals in research. Young adult (2–3 month old)
and aged (18–20 month old) C57Bl/6 mice were purchased from Charles River Laboratories
(CRL). Male and female TRPM2 KO (TRPM2−/−) mice were provided by Dr. Perraud
(Knowles et al., 2011) and corresponding WT mice were purchased from The Jackson
Laboratory (JAX). All mice were permitted access to water and standard lab chow ad
libitum with standard 12-h light/dark cycles. All experiments were performed in a blinded
and randomized manner according to the ARRIVE guidelines (Kilkenny et al., 2010a;
Kilkenny et al., 2010b), with a separate investigator generating the experimental code.
2.2. Novel inhibitor of TRPM2
We generated a cell permeable peptide-inhibitor of TRPM2 by fusing a portion of the Cterminus that corresponds > 90% with the Nudix domain (M2NX) of the C-terminus of
TRPM2channelswith the tat inducer of HIV (tat-M2NX). In addition, a control peptide,
which contained the same amino acids in a scrambled sequence (tat-SCR), was generated.
Dose of tat-M2NX was chosen based upon previous literature using tat-fusion proteins for
neuroprotection which utilized 8–9 mg/kg (Cao et al., 2002; Soriano et al., 2008).
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2.3. In vitro inhibition of TRPM2 channels
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HEK-293 cells stably expressing tetracycline-regulated FLAG-tagged human TRPM2 were
used. TRPM2 expressing HEK-293 cells were grown in Dulbecco's modified Eagle's
medium (Gibco) supplemented with 10% fetal bovine serum, L-glutamine (2 mM), and
penicillin/streptomycin (100 units/mL) at 37 °C in a 5% CO2 incubator. HEK cells were
grown in media containing doxycycline (1 µg/mL) to drive TRPM2 expression 24 h prior to
experiments. Cells were pre-incubated for 2 h with 50 µL of doxycycline-containing media
with tat-M2NX (25, 50, and 100 µM), tat-SCR (25, 50, and 100 µM) or vehicle. Fluo-5F
AM (Life Technologies, 10 µM), a membrane permeable Ca2+ indicator, was added to the
media during the last 30 min of incubation. Cells were washed twice and placed in 50 µL of
saline solution (135 mM NaCl, 5mMKCl, 1mMMgCl2, 1mMCaCl2, 10mMHEPES; pH 7.4).
Fluorescence was measured using a microplate reader (BioTek Synergy 2) and Gen5
software to measure fluorescence (485/20, 528/20) every 20 s before and after exposure to
H2O2 (200 µM final concentration) or saline (control).
2.4. Middle cerebral artery occlusion (MCAO)
Transient focal cerebral ischemia (60 min) was induced using reversible MCAO through the
intra-luminal filament techniques described previously (Shimizu et al., 2013). Briefly, mice
were anesthetized with isoflurane delivered through a face mask (5% induction and 1–
2%maintenance). Cerebral ischemia was induced for 60 min of MCAO via intraluminal
Exp Neurol. Author manuscript; available in PMC 2017 January 17.
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suture method (6-0 nylon monofilament coated with silicone to diameter of 0.22–0.24 mm).
Adequacy of MCAO confirmed by laser Doppler flowmetry (Moor Instruments) over the
right parietal cortex (> 80% drop required).
2.5. Infarct volume analysis
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After the corresponding reperfusion period, the mice were anesthetized with 5% isoflurane
and decapitated for brain collection. The mice were excluded from the study if subarachnoid
hemorrhage was observed. Each cerebrum was sliced into four 2-mm-thick coronal sections.
The sections were placed in 1.2% of 2,3,4-triphenyltetrazolium chloride (TTC, Sigma) for
30 min at 37 °C and fixed in 10% formalin for 24 h. Each coronal slice was stained and
photographed on both sides using a digital camera, infarction was measured with ImageJ
(NIH), and integrated across all five slices. In order to include the effect of edema, the
infarct volume was estimated indirectly and plotted as percentage of the contralateral
structure and presented as a corrected hemisphere infarct.
2.6. Testosterone and dihydrotestosterone enzyme-linked immunoassay
A cohort of naïve male mice was sacrificed by Avertin overdose (intraperitoneal) for blood
sample collections from the right ventricle of the heart using heparinized syringes. The
blood sample was centrifuged at 3300g for 10min at 4 °C to yield serum for hormone
detection. Enzyme-linked immunoassay for testosterone (Calbiotech) and
dihydrotestosterone (DHT, Alpha Diagnostic International, TX) were performed following
the manufacturers protocol.
2.7. Statistical analysis

Author Manuscript

All data are presented as mean±SEM. Each n represents an individual culture for in vitro
experiments and an individual animal for in vivo experiments. All experiments were
performed in a randomized and blinded manner, with analysis and surgery performed by
separate investigators. Statistical significance was determined using students t-test (unpaired,
2-tailed) for 2 groups and one-way analysis of variance (ANOVA) with Newman-Keuls post
hoc analysis or studies with > 2 groups. Statistical significance was established at p < 0.05.

3. Results
3.1. tat-M2NX inhibits the human TRPM2 channel in vitro

Author Manuscript

In order to determine the ability of tat-M2NX to inhibit TRPM2 channels, we used
HEK-293 cells stably expressing tetracycline-induced human FLAG-tagged TRPM2 channel
(hTRPM2). TRPM2 channel activity was measured using the Ca2+ indicator Fluo-5F to
monitor changes in fluorescence following treatment with 200 µM H2O2. Exposure to H2O2
increased fluorescence in HEK-293 cells expressing hTRPM2, while no changes were
observed in non-induced HEK-293 cells, indicating functionality of the channel in the in
vitro system (Fig. 1A & B). HEK-293 expressing the hTRPM2 had reduced H2O2-induced
Ca2+ influx after 2 h incubation with 100 µM tat-M2NX, while treatment with the tat-SCR
peptide had no effect on H2O2-induced Ca2+ influx (Fig. 1A & B). Further experiments
revealed a concentration-dependent decrease in Ca2+ influx following exposure to 25, 50,
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and 100 µM tat-M2NX in hTRPM2 expressing HEK-293 cells (Fig. 1A & B). These data
suggest that tat-M2NX inhibits human TRPM2 channels.
3.2. tat-M2NX reduces infarct volume in male brains, but not female brains

Author Manuscript

To investigate the effects of tat-M2NX on ischemic injury following experimental stroke,
male and female WT mice were subjected to 60 min transient MCAO and total hemisphere
infarct volume was analyzed. Either tat-M2NX or tat-SCR was injected 20 min prior to
occlusion of the MCA and infarct volume was analyzed 24 h after reperfusion. MCA
occlusion was similar in all groups tested, measured by laser Doppler flowmetry (Table 1)
and importantly, no effect of tat-M2NX was observed on blood pressure (Supplemental Fig.
1). Males treated with tat-M2NX showed smaller infarct volume compared to tat-SCR (29.2
± 4.6% [n = 8] vs. 43.4 ± 3.2% [n= 8; p < 0.01]), respectively (Fig. 1). In contrast, there was
no difference in infarct size after stroke in female mice exposed to tat-SCR (46.6 ± 2.1% [n
= 7]) or tat-M2NX (45.1 ± 2.1% [n = 7], Fig. 1). Together, these data demonstrate the ability
of tat-M2NX to produce male-specific neuroprotection, as previously described using CTZ
(Jia et al., 2011; Verma et al., 2012; Shimizu et al., 2013).
3.3. tat-M2NX provides no further protection compared to TRPM2 knockout
To further characterize the specificity of tat-M2NX for TRPM2 channels, we compared the
neuroprotective efficacy of tat-M2NX inTRPM2 knock out mice (TRPM2−/−). Infarct
volume was reduced in male TRPM2−/− compared to WT male mice, 27.3 ± 5.1% (n = 8) vs.
46.1±6.0% (n=7; p < 0.05), respectively (Fig. 2). There was no difference in infarct volume
observed between WT and TRPM2−/− females, (35.0 ± 4.6% [n = 9] vs. 44.2 ± 3.2% [n = 6],
Fig. 2). Administration of tat-M2NX did not further reduce infarct volume in male
TRPM2−/−, providing further evidence of specificity for TRPM2 channels by tat-M2NX.
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3.4. tat-M2NX demonstrates a translation-relevant therapeutic window
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Clinical trials in stroke have failed for a variety of reasons, but many have failed due to a
relevant therapeutic window (Neuhaus et al., 2014; Tymianski, 2014). Therefore, we tested
whether tat-M2NX administered 3 h after reperfusion (4 h after onset of ischemia) in WT
male mice can provide neuroprotection. tat-M2NX or tat-SCR was administered retroorbitally 3 h post-reperfusion and the brain was collected at either 24 h or 96 h after
injection to analyze the extent of infarct size. tat-M2NX significantly reduced infarct volume
at 24 h and 96 h post-stroke compared to tat-SCR (Fig. 3, 24 h: tat-SCR 46.5 ± 7.3% (n = 6)
vs. tat-M2NX 28.3 ± 13.5% (n = 7, p < 0.05); 96 h: tat-SCR 41.4 ± 8.0% (n = 8) vs. tatM2NX 23.8 ± 12.5% (n = 8, p < 0.05)). In contrast, administration of the non-selective
TRPM2 inhibitor clotrimazole (CTZ) 3 h after reperfusion had no effects on infarct volume
(Fig. 3, vehicle 47.0 ± 9.9% vs. CTZ 46.8 ± 7.4%). This data suggests that not only is tatM2NX neuroprotective, but also has a wider therapeutic window than CTZ and is similar to
the clinical intervention of tPA.
3.5. tat-M2NX provides neuroprotection in aged male mice
The incidence of stroke increases with age among all races and both sexes (Herson et al.,
2009; Mozaffarian et al., 2015). Therefore, we tested whether tat-M2NX would provide
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protection in aged mice. 18–20 month-old male and female mice were subjected to 60 min
MCAO and tat-M2NX or tat-SCR was administered 30min after reperfusion. Infarct volume
was analyzed 24 h later. Consistent with the data from young adults, aged male mice given
tat-M2NX had smaller infarct volumes compared to aged males given tat-SCR (27.0 ± 0.7%
[n = 6] vs. 34.6±1.7% [n=6], respectively [Fig. 4]; p < 0.01). Interestingly, control aged male
mice (tat-SCR treated) had smaller infarcts compared to young adult (YA) mice, consistent
with previous reports (Liu et al., 2009a) (27.0 ± 0.7% [n = 6] vs. 52.1 ± 2.7% [n = 6],
respectively [Fig. 4]). In contrast, tat-M2NX did not provide neuroprotection in aged
females compared to tat-SCR (40.2 ± 4.0% [n = 6] vs. 41.5 ± 4.5% [n = 6], Fig. 4). Together,
these data suggest that TRPM2 channels contribute to acute ischemic cell death following
stroke in aged males, but not in females.

4. Discussion
Author Manuscript

This study presents data showing that a novel inhibitor of TRPM2, tat-M2NX, can
dramatically decrease infarct volume in males. Further, our data shows that the novel peptide
has specificity for TRPM2 by way of blocking TRPM2-mediated Ca2+ entry in vitro and
exhibiting a ceiling effect with TRPM2−/− mice. tat-M2NX appears to have a therapeutic
window similar to that of tPA, giving hope that inhibiting TRPM2 channels with this novel
peptide will have translational potential. To further the translational potential, our data
indicate that tat-M2NX is effective in reducing infarct size in aged males, thereby targeting a
population that has increased risk for focal ischemia.
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TRPM2 channels have been implicated in ischemic neuronal damage for over a decade, yet
the field has been plagued by lack of an inhibitor specific for the channel (Jiang et al., 2011).
Here we present the characterization of a novel and specific peptide inhibitor of TRPM2
channels, tat-M2NX. The observation that tat-M2NX inhibits human TRPM2 channels
presents translational intrigue and the possibility that this peptide could be used in clinical
conditions. Currently, tat-bound peptides are being used in clinical trials (Hill and Fitch,
2012), representing a potential therapeutic strategy for human pathology. A distinguishing
property of TRPM2 channels is that they are gated by adenosine-5′-diphosphoribose
(ADPr), via binding to an ADPr hydrolase (term NUDT9-H) homology domain in the Cterminus (Perraud et al., 2001). The catalytic domain of NUDT9-H is the Nudix domain,
which in coordination with several distant amino acids form the ADPr binding pocket (Shen
et al., 2003; Kuhn and Luckhoff, 2004). We targeted the ADPr binding pocket as a strategy
to inhibit channel activation, as mutations in this domain render the channel inactive (Kuhn
and Luckhoff, 2004). Therefore, we generated a peptide (M2NX), fused to cell permeable tat
sequence (tat 47–57) that inhibits TRPM2 channel activity via interaction with the ADPr
binding pocket of the NUDT9-H domain of the channel. This rational design, coupled with
our data showing a ceiling effect with TRPM2−/− mice, gives us great confidence in the ion
channel specificity for TRPM2.
Current data using tat-M2NX is consistent with our previous studies using the less specific
TRPM2 inhibitor CTZ or shRNA, demonstrating efficacy specifically in males. Interestingly,
the current study uses a second TRPM2 KO mouse and observed the same male-specific
protection observed previously (Shimizu et al., 2013), indicating the phenomena is
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independent of strain. Sex differences in outcomes following stroke are well described and
emerging data suggests discrete cell death pathways triggered after cerebral ischemia in
male or female animals (Herson et al., 2009; Siegel et al., 2010). Male mice demonstrate
activation of cell death pathways predominantly mediated by excessive reactive oxygen
species production and subsequent over-activation of poly(ADP-ribose) polymerase-1
(PARP-1) (Goto et al., 2002; Siegel et al., 2010). This pathway ultimately leads to the
release of apoptosis-inducing factor following mitochondrial dysfunction, resulting in cell
death. In contrast, cell death pathways in females involve caspase dependent apoptosis (Zhu
et al., 2005; Zhu et al., 2006). The male-specific over-activation of PARP-1 in cell death
following cerebral ischemia is particularly relevant to the data here, as PARP-1 generates
adenosine-5′-diphosphoribose (ADPr), which goes on to activate TRPM2 channels (Perraud
et al., 2001; Perraud et al., 2005; Hill et al., 2006; Eisfeld and Luckhoff, 2007; Buelow et al.,
2008; Shimizu et al., 2013). We have taken advantage of this signaling pathway in designing
tat-M2NX that targets the ADPr binding pocket of TRPM2, thereby inhibiting its activation.
The possibility remains that the lack of effect in females could be due to inadequate dosing
of tat-M2NX, though we have performed extensive studies using in vitro neuronal cultures
and TRPM2 KO mice in combination with several known TRPM2 channel inhibitors and
have never observed a protective effect in female cells or animals (Jia et al., 2011; Verma et
al., 2012; Nakayama et al., 2013; Shimizu et al., 2013; Quillinan et al., 2014). Therefore, it
is highly unlikely that the lack of protection observed in female mice in the current study
using tat-M2NX is related to incorrect dosing. As such, the male-specific activity of tatM2NX is consistent with previous data and entirely expected by the design of the peptide.
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This study makes use of aged animals to demonstrate continued efficacy in older animals.
Much has been written about the need for aged animal studies in preclinical studies (Herson
and Traystman, 2014; Neuhaus et al., 2014), however relatively few studies report the
interaction between age and treatment. This issue is particularly relevant given the changes
in androgen levels at older ages (Gray et al., 1991) and the activation of TRPM2 channels by
androgen related pathway (Shimizu et al., 2013). Therefore it may be speculated that low
androgens in aged male mice would cause the loss of tat-M2NX neuroprotection. We
assessed serum levels of testosterone and the higher potency dihydrotestosterone (DHT)
across the mouse lifespan. Testosterone levels were decreased in older mice compared to
young adults, however there was no change across ages in the higher potency
dihydrotestosterone (DHT) (Supplemental Fig. 2), suggesting that DHT levels remain
sufficiently high to engage TRPM2 channels in aged male mice. Despite this, our data,
consistent with previous observations (Shapira et al., 2002; Liu et al., 2009b; Manwani et al.,
2013), reveal that aged males have smaller infarcts than younger males. In contrast, aged
female mice have larger infarcts than young females, as previously described (Liu et al.,
2009b). Together, the data presented here represent an important pre-clinical study using a
novel peptide to block TRPM2 channels and reduce infarct volume in males, but not
females.
One of the major goals of ischemia research has been to develop neuroprotectants that could
reduce ischemic damage. With the exception of recombinant tissue plasminogen activator,
little preclinical research has translated into effective stroke therapies. It has been noted that
many failures have been due to widespread use of young male animals and insufficient
Exp Neurol. Author manuscript; available in PMC 2017 January 17.
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therapeutic windows (Neuhaus et al., 2014). Further, prior to recent advances in
thrombectomy and revascularization strategies (Palaniswami and Yan, 2015), delivery of
neuroprotectants after stroke was most likely non-efficacious. However, now that
thrombectomy and revascularization are becoming standard in stroke treatment, reperfusion
and oxidative stress targets such as TRPM2 are extremely attractive. Indeed, we report here
in our transient focal ischemia model that tat-M2NX reduces injury after reperfusion.
Importantly, we observed a relatively wide therapeutic window for tat-M2NX as a
neuroprotectant (≥4 h). This is consistent with our understanding of the mechanism of
TRPM2 channel regulation. Data clearly implicates NMDA receptor over-activation
(excitotoxicity) as an early initiating event in ischemic injury, triggering a cascade of
deleterious events, including oxidative stress and apoptosis. However, glutamate receptor
blockade and antioxidant therapies have failed in clinical trials. Therefore, we and others
have focused on downstream signaling pathways that may provide both improved specificity
and wider therapeutic window of opportunity. Indeed, our data indicating a window of
opportunity for our novel TRPM2 inhibitor (tat-M2NX) of at least 4 h is consistent with its
role as an oxidative-stress activated signaling pathway downstream of NMDA receptor overactivation and consequent oxidative stress. This is equivalent to the guidelines for rTPA use
published by the American Stroke Association (Powers et al., 2015). While there are some
situations where rTPA can be given later (Powers et al., 2015), the data presented here are
within the therapeutic window of the current standard of care, and likely relevant after
endovascular thrombectomy. Interestingly, we report here that clotrimazole, a non-specific
inhibitor of TRPM2, does not offer a similar therapeutic window, though we have shown
previously that CTZ can provide protection when given up to 2 h after induction of MCAO
(Shimizu et al., 2013). The mechanisms whereby CTZ has a shorter therapeutic window
remain unknown. Nonetheless, the therapeutic window of tat-M2NX demonstrated here
make tat-M2NX a potential therapeutic avenue for stroke.

5. Summary
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The current study demonstrates that a specific inhibitor of TRPM2 channels can reduce
stroke injury in a sexually dimorphic manner. The ability of tat-M2NX to inhibit a human
homolog of TRPM2, combined with efficacy in aged animals and clinically relevant
therapeutic window allows for optimism that this agent can someday be used in combination
with other ischemia therapies to improve outcomes in people suffering from stroke. While
this study does not address the important issues of comorbidities and behavioral outcomes
that often complicate translation, our data provide important proof of concept for a novel
strategy to combat stroke. As outlined above, we make use of both males and females to
show that TRPM2 is an important contributor in male ischemic damage, but the same is not
true for females. The majority of human clinical trials do not power to assess sex differences
in efficacy and are therefore not investigated. Further, we show that tat-M2NX can
effectively decrease infarct volume when given at least 4 h after onset of symptom. However,
a potential weakness of the current study is the reliance on histological measurements to
assess the protective efficacy of tat-M2NX. Future studies will need to assess the functional
outcomes of such a therapeutic approach. As such, the current study provides important
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insights into the mechanisms of TRPM2-related cell death and begins to reveal strategies
that may be targeted to reduce ischemic impairments.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
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tat-M2NX inhibits Ca2+ influx through TRPM2 channels and provides in vivo
neuroprotection. (A) Average fluorescent changes in Fluo-5F fluorescence shown as
percentage increase from baseline in HEK-293 cells expressing tetracycline-regulated
cytomegalovirus-driven transcription of FLAG-tagged human TRPM2. Samples were treated
with treated with 100 µM tat-M2NX (green) or tat-SCR (black) in the presence of 200
µMH2O2. (B) Quantification of percentage increase in Fluo-5F fluorescence in HEK-293
cells treated with 25, 50, 100 µM tat-M2NX or 100 µM tat-SCR. (C) TTC staining from
male brains treated with (C') tat-SCR (n= 8) and (C") tat-M2NX (n= 8), and female brains
treated with (C*) tat-SCR (n= 7) and (C**) tat-M2NX (n= 7) 20 min prior to MCAO. (E)
Quantification of percentage of infarct volume in WT male and female mice treated with
vehicle, 20 mg/kg tat-SCR, or 20 mg/kg tat-M2NX.
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Fig. 2.

tat-M2NX does not protect TRPM2−/− mice following 60 min tMCAO. Quantification of
percentage of infarct volume from WT and TRPM2−/− mice brains stained with TTC.
TRPM2−/− male mice were treated with 20 mg/kg tat-M2NX peptide or vehicle.
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Fig. 3.

tat-M2NX exhibits a clinically relevant therapeutic window. (A) Representative TTC
staining of male mice treated with tat-SCR (A') or tat-M2NX (A") 3 h after reperfusion and
stained 24 h after reperfusion and male mice treated with tat-SCR (B') or tat-M2NX (B") 3 h
after reperfusion and stained 96 h after reperfusion. (C) Quantification of percentage of
infarct volume in male and female brains stained with TTC 24 h and 96 h after receiving
drug. Male and female mice were treated with vehicle, clotrimazole (CTZ), tat-SCR (20
mg/kg) or tat-M2NX (20 mg/kg).
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Fig. 4.

tat-M2NX provides neuroprotection in aged males. Quantification of percentage of infarct in
18–20 month old male and female mice receiving either tat-SCR (SCR) or tat-M2NX
(M2NX). YA= young adult; A = aged. *p < 0.05.
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LDF and tympanic temperature.
LDF (%)

Temperature (°C)

Just before reperfusion

Reperfusion 5 min

Rectal

Tympanic

Male + tat-M2NX (n = 8)

9±1

76 ± 4

36.6 ± 0.2

36.8 ± 0.3

Male + tat-SCR (n = 8)

9±1

72 ± 5

36.8 ± 0.1

36.6 ± 0.2

Female + tat-M2NX (n = 7)

7±1

69 ± 3

36.7 ± 0.1

36.7 ± 0.2

Female + tat-SCR (n = 7)

6±1

87 ± 10

36.8 ± 0.1

36.7 ± 0.1

JAX WT male (n = 7)

7±1

70 ± 6

36.6 ± 0.1

36.8 ± 0.2

JAX WT female (n = 7)

10 ± 3

91 ± 10

36.4 ± 0.1

36.5 ± 0.1

TRPM2 KO male (n = 7)

12 ± 3

75 ± 5

36.6 ± 0.1

37.2 ± 0.2

TRPM2 KO female (n = 6)

Author Manuscript

8±2

88 ± 9

36.3 ± 0.2

36.5 ± 0.3

12 ± 2

88 ± 14

36.7 ± 0.2

36.7 ± 0.1

tat-M2NX 3 h 1 d (n = 7)

8±1

79 ± 4

36.6 ± 0.1

36.5 ± 0.2

tat-SCR 3 h 1 d (n = 6)

8±2

82 ± 13

36.7 ± 0.2

36.7 ± 0.2

tat-M2NX 3 h 4 d (n = 8)

9±1

91 ± 6

36.8 ± 0.1

36.8 ± 0.1

tat-SCR 3 h 4 d (n = 8)

9±1

72 ± 3

36.9 ± 0.1

36.8 ± 0.1

TRPM2 KO male + tat-M2NX (n = 5)

Abbreviations: 1 d, 24 h reperfusion; 4 d, 96 h reperfusion; JAX; Jackson Laboratory, LDF, laser-Doppler flowmetry; MCAO, middle cerebral
artery occlusion; TRPM2 KO, transient receptor potential M2 knockout mice; WT, wild type.
Values are mean ± SEM. No statistical differences were observed between groups using one-way ANOVA.
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